← Back to patent-cliff list
AUR-109
Tier C — Watch / tradeAUR-109
Orion Corporation
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：FGFR1, FGFR2, FGFR3, FGFR4, VEGFR1, VEGFR2, VEGFR3
Indications (approved)：Bladder cancer, Lung cancer, Pulmonary fibrosis, Liver cancer, Ovarian cancer, Breast cancer, Renal cell carcinoma, Colorectal cancer
Regional status
US
-
EU
No progress
2014-09-18
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of AUR-109?
Approved indications include: Bladder cancer, Lung cancer, Pulmonary fibrosis, Liver cancer, Ovarian cancer, Breast cancer, Renal cell carcinoma, Colorectal cancer.
When does the AUR-109 patent expire?
No public expiry year is available for AUR-109 yet; this page updates once verified.
How do I get a quote for AUR-109 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-01